Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
METSAFE
NCT07027969Phase 4Not yet recruiting
- Start
- Nov 2026
- Primary completion
- Dec 2029
- Countries
- 1
01
Overview
Phase 4, randomised, open-label trial in Atrial fibrillation (AFib) and obesity (2 arms). Primary endpoint: Relative change in total duration of being in atrial fibrillation at 52 weeks. Planned start Nov 2026; status: not yet recruiting.
02
Conditions
Atrial fibrillation (AFib)obesity
Beyond the preview
Go deeper on NCT07027969.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT07027969.